Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr Zeidan on Imetelstat in Lower-Risk MDS

June 2nd 2023

Amer Zeidan, MBBS, discusses topline efficacy findings from the IMerge trial of imetelstat in patients with transfusion-dependent lower-risk myelodysplastic syndrome.

Imetelstat Prolongs Transfusion Independence, Increases Hemoglobin in R/R MDS

June 2nd 2023

Treatment with the first-in-class direct and competitive telomerase inhibitor imetelstat resulted in statistically significant and clinically meaningful efficacy in patients with heavily transfusion dependent, non-del(5q) lower-risk myelodysplastic syndrome that is relapsed or refractory to erythropoiesis stimulating agents, according to findings from the phase 3 IMerge trial.

Luspatercept Nearly Doubles Likelihood of Transfusion Independence in Lower-Risk MDS

May 25th 2023

Luspatercept-aamt led to a higher rate of sustained transfusion independence compared with erythropoiesis stimulating agents in patients with ESA-naïve, lower-risk myelodysplastic syndrome.

NCCN Guidelines List Ropeginterferon Alfa-2b as Preferred Treatment in Polycythemia Vera

May 24th 2023

The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology have been revised to include ropeginterferon alfa-2b-njft as a preferred treatment option for patients with high- and low-risk polycythemia vera, irrespective of treatment history.

FDA Approves Avapritinib for Indolent Systemic Mastocytosis

May 22nd 2023

The FDA has approved avapritinib (Ayvakit) for the treatment of adults with indolent systemic mastocytosis.

MAJIC-PV Trial Confirms Clinical Benefit of Ruxolitinib in Polycythemia Vera

May 19th 2023

Treatment with ruxolitinib generated superior responses vs treatment with best available therapy in patients with hydroxycarbamide-intolerant or -resistant polycythemia vera, according to findings from the phase 2 MAJIC-PV trial.

Dr Mascarenhas on Ongoing Research in Myelofibrosis

May 18th 2023

John Mascarenhas, MD, discusses ongoing trials and research in myelofibrosis.

Dr Mascarenhas on First-line Treatment Decisions in Myelofibrosis

May 16th 2023

John Mascarenhas, MD, discusses first-line treatment decisions for patients with myelofibrosis.

ECLIPSE PV Trial Begins Ropeginterferon Alfa-2b Dosing in Polycythemia Vera

May 15th 2023

The first patients have been dosed in the phase 3b ECLIPSE PV trial, which is evaluating an accelerated dosing schedule of ropeginterferon alfa-2b-njft for the treatment of patients with polycythemia vera.

Dr Mascarenhas on the Background of the MANIFEST-2 Trial in Myelofibrosis

May 11th 2023

John Mascarenhas, MD, discusses the background of the phase 3 MANIFEST-2 trial investigating the combination of pelabresib and ruxolitinib vs ruxolitinib plus placebo in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.

Dr Jain on Baseline Differences Across Different Donor Types in Myelofibrosis

May 10th 2023

Tania Jain, MBBS, discusses notable differences in baseline characteristics and donor sequencing, according to a retrospective study of patient outcomes following blood or marrow transplant in 4 common donor types of myelofibrosis.

MANIFEST-2 Study of Pelabresib Plus Ruxolitinib Completes Enrollment in Myelofibrosis

May 9th 2023

Enrollment to the phase 3 MANIFEST-2 trial, which is examining the safety and efficacy of pelabresib plus ruxolitinib vs ruxolitinib alone in patients with JAK inhibitor–naïve myelofibrosis, has completed and topline findings are anticipated by the end of 2023.

Roxadustat Misses Mark as Anemia Treatment in Transfusion-Dependent, Lower-risk MDS

May 5th 2023

The phase 3 MATTERHORN trial examining roxadustat as an anemia treatment in patients with transfusion-dependent, lower-risk myelodysplastic syndrome did not meet its primary end point.

Dr Patel on How the Timing of ASCT Affects Post-Transplant Complications in Myelofibrosis

May 4th 2023

Sagar Patel, MD, discusses how the timing of autologous stem cell transplant can affect outcomes in those with myelofibrosis, including the risk of patients developing post-transplant complications.

Individual Patient Factors Drive Treatment Decisions in MPNs

May 4th 2023

Onco-nursing experts highlight the best practices and latest treatment regimens for patients presenting with the 3 most common myeloproliferative neoplasms: myelofibrosis, polycythemia vera, and essential thrombocythemia.

Looking Ahead in Treating Myeloproliferative Neoplasms

April 26th 2023

Shared closing thoughts on the future treatment landscape for myeloproliferative neoplasms, including future and emerging areas of research and remaining areas of unmet need.

Potential Combination Therapy Approaches with Ruxolitinib in Myelofibrosis

April 26th 2023

A review of recent trial data evaluating combination therapy approaches with ruxolitinib in myelofibrosis, including the rationale and potential clinical benefits associated with the use of these emerging strategies.

Selinexor/Ruxolitinib Combo Elicits Sustained Spleen Responses, Improves Symptoms in Myelofibrosis

April 21st 2023

The combination of selinexor at 60 mg and ruxolitinib induced rapid and durable spleen responses and improved symptoms at weeks 12 and 24 in patients with treatment-naïve myelofibrosis, according to updated data from the phase 1 XPORT-MF-034 trial.

Novel Therapies Under Investigation for Myelofibrosis

April 19th 2023

Focused discussion on emerging trial data surrounding novel, investigational therapies for myelofibrosis.

Treatment Sequencing Approaches for Myelofibrosis

April 19th 2023

Expert perspectives on treatment sequencing strategies with JAK inhibitors for myelofibrosis.